X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2017 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare, Analyse VENUS REMEDIES with ACTAVIS INC. - US - Equitymaster
  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

VENUS REMEDIES vs ACTAVIS (US) - Comparison Results

ACTAVIS (US)
   Change

Actavis, Inc. is a global, integrated specialty pharmaceutical company focused on developing, manufacturing and distributing generic, brand and biosimilar products. It develops, manufactures and market generic, branded generic, legacy brands and Over... More

DO YOU LIKE THESE REPORTS? TELL US!

Financials

 VENUS REMEDIES   ACTAVIS
EQUITY SHARE DATA
    VENUS REMEDIES
Mar-16
ACTAVIS
Dec-14
VENUS REMEDIES/
ACTAVIS
5-Yr Chart
Click to enlarge
High Rs21817,503-   
Low Rs8210,676-   
Sales per share (Unadj.) Rs365.63,151.8-  
Earnings per share (Unadj.) Rs1.5-393.3-  
Cash flow per share (Unadj.) Rs37.9289.2-  
Dividends per share (Unadj.) Rs00-  
Dividend yield (eoy) %00-  
Book value per share (Unadj.) Rs382.56,836.1-  
Shares outstanding (eoy) m11.44265.90-   
Bonus/Rights/Conversions ---  
Price / Sales ratio x0.44.5 9.2%   
Avg P/E ratio x101.0-35.8 -281.9%  
P/CF ratio (eoy) x4.048.7 8.1%  
Price / Book Value ratio x0.42.1 19.0%  
Dividend payout %00-   
Avg Mkt Cap Rs m1,7173,746,408 0.0%   
No. of employees `0001.021.6 4.7%   
Total wages/salary Rs m3240-   
Avg. sales/employee Rs Th4,100.738,799.0 10.6%   
Avg. wages/employee Rs Th318.00-   
Avg. net profit/employee Rs Th16.7-4,841.7 -0.3%   
INCOME DATA
Net Sales Rs m4,183838,058 0.5%  
Other income Rs m20-2,092 -1.0%   
Total revenues Rs m4,203835,966 0.5%   
Gross profit Rs m812107,660 0.8%  
Depreciation Rs m417181,470 0.2%   
Interest Rs m38026,434 1.4%   
Profit before tax Rs m35-102,335 -0.0%   
Minority Interest Rs m00-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m0-7,507 0.0%   
Tax Rs m18-5,261 -0.3%   
Profit after tax Rs m17-104,581 -0.0%  
Gross profit margin %19.412.8 151.0%  
Effective tax rate %51.65.1 1,003.0%   
Net profit margin %0.4-12.5 -3.3%  
BALANCE SHEET DATA
Current assets Rs m2,771441,549 0.6%   
Current liabilities Rs m1,931322,019 0.6%   
Net working cap to sales %20.114.3 140.7%  
Current ratio x1.41.4 104.6%  
Inventory Days Days12558 215.5%  
Debtors Days Days5466 81.1%  
Net fixed assets Rs m5,328102,335 5.2%   
Share capital Rs m1140-   
"Free" reserves Rs m4,1770-   
Net worth Rs m4,3761,817,717 0.2%   
Long term debt Rs m1,911952,519 0.2%   
Total assets Rs m8,4283,331,277 0.3%  
Interest coverage x1.1-2.9 -38.0%   
Debt to equity ratio x0.40.5 83.3%  
Sales to assets ratio x0.50.3 197.3%   
Return on assets %4.7-2.3 -200.7%  
Return on equity %0.4-5.8 -6.8%  
Return on capital %6.6-3.0 -219.2%  
Exports to sales %00-   
Imports to sales %20.50-   
Net fx Rs m-8580-   
CASH FLOW
From Operations Rs m469143,911 0.3%  
From Investments Rs m29-344,578 -0.0%  
From Financial Activity Rs m-464193,603 -0.2%  
Net Cashflow Rs m35-7,064 -0.5%  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster
The reporting currency for ACTAVIS (US) is United States Dollars. All data has been converted at 64.16 Rs / USD

Compare VENUS REMEDIES With: ADCOCK INGRAM (S. Africa)  MYLAN (US)  TEVA PHARMA (Israel)  

Compare VENUS REMEDIES With: AUROBINDO PHARMA  UNICHEM LAB  PLETHICO PHARMA  DR. DATSONS LABS  DISHMAN PHARMA  



Today's Market

Global Markets Remain Volatile Ahead of US Growth Concerns(RoundUp)

Benchmark indices in US corrected marginally by 0.8% during the week. Minutes of Federal Reserve's July meeting are out and the situation looks to be in favor of the emerging markets.

Related Views On News

Sun Pharma: Bottomline Slips into the Red Amidst Challenging Environment (Quarterly Results Update - Detailed)

Aug 14, 2017

A challenging environment and one-time expense pushes Sun Pharma into a loss in the first quarter.

Lupin: Bigger Challenges or Bigger Margin of Safety? (Quarterly Results Update - Detailed)

Aug 14, 2017

GST impact coupled with price erosion in US leads to lower profits for the quarter.

Dr Reddy's: US Pressure Continues to Haunt (Quarterly Results Update - Detailed)

Aug 8, 2017

Profits plunge due to higher raw material costs.

Biocon: Lower Licensing Income Leads to Muted Growth for the Quarter (Quarterly Results Update - Detailed)

Jun 23, 2017

Net Profit lower due to exceptional items in the previous year.

Sun Pharma: Price Erosion in US Impacts Growth (Quarterly Results Update - Detailed)

May 30, 2017

US markets decline while other geographies grow in the quarter.

More Views on News

Most Popular

Demonetisation Barely Made Any Difference to Tax Collections(Vivek Kaul's Diary)

Aug 7, 2017

The data tells us quite a different story from the one the government is trying to project.

A 'Backdoor' to Multibaggers: It's Like Investing in Asian Paints Ten Years Ago(The 5 Minute Wrapup)

Aug 10, 2017

Don't miss these proxy bets on growing companies or in a few years you will be looking back with regret.

Should You Invest In Bharat-22 ETF? Know Here...(Outside View)

Aug 8, 2017

Bharat-22 is one of the most diverse ETFs offered so far by the Government. Know here if you should invest...

Signs of Life in the India VIX(Daily Profit Hunter)

Aug 12, 2017

The India VIX is up 36% in the last week. Fear has gone up but is still low by historical standards.

7 Financial Gifts For Your Sister This Raksha Bandhan(Outside View)

Aug 7, 2017

Raksha Bandhan signifies the brother-sister bond. Here are 7 thoughtful financial gifts for sisters...

More

Become A Smarter Investor In
Just 5 Minutes

Multibagger Stocks Guide 2017
Get our special report, Multibagger Stocks Guide (2017 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

VENUS REMEDIES SHARE PRICE


Aug 18, 2017 (Close)

TRACK VENUS REMEDIES

  • Track your investment in VENUS REMEDIES with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON VENUS REMEDIES

VENUS REMEDIES 5-YR ANALYSIS

COMPARE VENUS REMEDIES WITH

MARKET STATS